Bharat Biotech’s Covaxin shows 77.8% efficacy in phase 3
New Delhi : Bharat Biotech submitted its Phase 3 trial data recently and it showed 77.8% efficacy.
The Hyderabad-based firm had earlier submitted the trial data to the Subject Expert Committee (SEC) of the Indian drug regulator.
According to ANI report, the trial data has been approved by the expert panel. The trials were conducted on 25,800 subjects.
Covaxin is among the three vaccines which are being administered to the people in India. Other than this Covishield and Sputnik V have been approved for administration against the coronavirus.
The company has developed the vaccine in association with the Indian Council of Medical Research (ICMR).